

# Cancer-Associated Thrombosis: Beyond Clinical Practice Guidelines—A Multidisciplinary (SEMI–SEOM–SETH) Expert Consensus

Vanessa Pachón<sup>1</sup> Javier Trujillo-Santos<sup>2</sup> Pere Domènech<sup>3</sup> Enrique Gallardo<sup>4</sup> Carmen Font<sup>5</sup>  
José Ramón González-Porras<sup>6</sup> Pedro Pérez-Segura<sup>7</sup> Ana Maestre<sup>8</sup> José Mateo<sup>9</sup> Andrés Muñoz<sup>10</sup>  
María Luisa Peris<sup>11</sup> Ramón Lecumberri<sup>12</sup>

<sup>1</sup>Department of Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain

<sup>2</sup>Department of Internal Medicine, Hospital Universitario Santa Lucía, Cartagena, Spain

<sup>3</sup>Thrombosis and Haemostasis Unit, Hospital Universitario Bellvitge, L'Hospitalet de Llobregat, Catalonia, Spain

<sup>4</sup>Department of Oncology, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Spain

<sup>5</sup>Department of Medical Oncology, Hospital Clinic, Barcelona, Spain

<sup>6</sup>Hematology Service, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain

<sup>7</sup>Department of Oncology, Hospital Clínico San Carlos, Madrid, Spain

<sup>8</sup>Department of Internal Medicine, Hospital del Vinalopó, Elche, Spain

<sup>9</sup>Hematology Service, Hospital Santa Creu i Sant Pau, Barcelona, Spain

<sup>10</sup>Department of Oncology, Hospital Universitario Gregorio Marañón, Madrid, Spain

<sup>11</sup>Department of Internal Medicine, Hospital Provincial de Castellón, Castellón, Spain

<sup>12</sup>Hematology Service, Clínica Universidad de Navarra, IDISNA, CIBER-CV, Pamplona, Spain

Address for correspondence Ramón Lecumberri, MD, PhD, Hematology Service, University Clinic of Navarra, Av. Pío XII, 36, 31008 Pamplona, Spain (e-mail: rlecumber@unav.es).

TH Open 2018;2:e373–e386.

## Abstract

Despite the growing interest and improved knowledge about venous thromboembolism in cancer patients in the last years, there are still many unsolved issues. Due to the limitations of the available literature, evidence-based clinical practice guidelines are not able to give solid recommendations for challenging scenarios often present in the setting of cancer-associated thrombosis (CAT). A multidisciplinary expert panel from three scientific societies—Spanish Society of Internal Medicine (SEMI), Spanish Society of Medical Oncology (SEOM), and Spanish Society Thrombosis and Haemostasis (SETH)—agreed on 12 controversial questions regarding prevention and management of CAT, which were thoroughly reviewed to provide further guidance. The suggestions presented herein may facilitate clinical decisions in specific complex circumstances, until these can be made leaning on reliable scientific evidence.

## Keywords

- ▶ cancer
- ▶ venous thrombosis
- ▶ pulmonary embolism
- ▶ prophylaxis
- ▶ treatment

## Introduction

Cancer patients have a high risk of venous thromboembolism (VTE), sometimes being the first manifestation of a so-far


hidden malignancy. Mechanisms leading to thrombus formation in cancer patients are incompletely understood, although the risk may be partly influenced by the antineoplastic therapy

received  
April 12, 2018  
accepted after revision  
September 17, 2018

DOI <https://doi.org/10.1055/s-0038-1675577>  
ISSN 2512-9465.

© 2018 Georg Thieme Verlag KG  
Stuttgart · New York

License terms



itself. The management of cancer-associated thrombosis (CAT) frequently represents a challenge for clinicians due to very poor or lack of evidence regarding common daily practice scenarios that have also been poorly addressed by most currently available evidence-based guidelines.<sup>1–5</sup>

This work arises from a joint initiative of a multidisciplinary panel of experts under the auspice of the Spanish Society of Internal Medicine (SEMI), Spanish Society of Medical Oncology (SEOM), and Spanish Society of Thrombosis and Haemostasis (SETH), who leaned on literature to reach consensus on controversial issues aimed to guide clinicians to manage complex, albeit not uncommon, situations related to CAT, until further evidence supporting or discouraging the proposed recommendations becomes available. Our aim is not to produce another evidence-based guideline on the field but to provide useful advice for scenarios that clinicians involved in CAT have to face without the support of unequivocal strong evidence-based recommendations. Due to the specific wording of the questions, most of them have not been previously approached elsewhere.

## Methods

In the first meeting, the whole panel agreed on 12 specific controversial questions that were to be addressed. The topics were identified by a recent Delphi study and completed by own experience.<sup>6</sup> The questions were distributed among four teams of three experts, including one member of each society (i.e., three questions per team). For every topic, the available

literature (from previous guidelines to small studies) was reviewed and an initial consensus was reached inside each working team leading to a proposal of suggestions for the assigned questions. In the final meeting, the whole panel discussed all the proposals until agreement was reached. An executive summary is presented in **Table 1**, also including the most relevant literature for each topic.

## Results

### Question 1: In Ambulatory Cancer Patients, Should the Thrombotic Risk Be Evaluated Using a Risk Score to Decide on the Use of Antithrombotic Prophylaxis?

#### Background

To date, the only validated prediction model of CAT is the Khorana risk score.<sup>7</sup> However, in recent years several studies in different types of cancer suggest that this should not be the only tool to select candidate patients for antithrombotic prophylaxis in the outpatient setting<sup>8–11</sup>:

- A recent assessment questions the usefulness of the Khorana score, Vienna-CATS prediction model, PROTECHT score, or CONKO score for this aim.<sup>12</sup>
- Two recent models, COMPASS<sup>13</sup> and ONKOTEV,<sup>14</sup> which rely on clinical parameters only, seem to overcome the predictive ability of the Khorana score. At 6 months, the area under the curve (AUC) of receiving operating

**Table 1** Summary of recommendations

Question	Background	Suggestions
<b>Prophylaxis</b>		
1. In ambulatory cancer patients, should thrombotic risk be evaluated using a risk score to decide on the use of antithrombotic prophylaxis?	<ul style="list-style-type: none"> <li>• The accuracy of Khorana, Vienna-CATS, PROTECHT, or CONKO scores is limited.<sup>10–12</sup></li> <li>• COMPASS, ONKOTEV, and ONCO-THROMB require validation.<sup>13,14,16</sup></li> <li>• Some tumor-specific scores have been recently developed showing promising results.<sup>17,18</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Thrombotic risk should be evaluated, but not only by using the Khorana's risk score.</li> <li>• Attention has to be paid to new scores with improved predictive ability, although validation is required.</li> </ul>
2. In cancer patients who are hospitalized for an acute medical illness, when is pharmacological antithrombotic prophylaxis contraindicated?	<ul style="list-style-type: none"> <li>• Hospitalized cancer patients have a high risk of VTE and, whenever possible, preventive measures have to be implemented.<sup>1–5</sup></li> <li>• However, studies that weigh the risk-benefit balance in this specific population are lacking.</li> <li>• Therefore, safety must be specially considered in the clinical decision-making process.</li> </ul>	<ul style="list-style-type: none"> <li>• Absolute contraindications of pharmacological prophylaxis: <ul style="list-style-type: none"> <li>- Recent bleeding in CNS; active major bleeding; platelet count <math>&lt;20 \times 10^9/L</math>.</li> </ul> </li> <li>• Relative contraindications: <ul style="list-style-type: none"> <li>- Relevant chronic bleeding (duration <math>&gt;48</math> h); initial period of postneurosurgery; spinal or intracranial lesions; platelet count <math>20\text{--}50 \times 10^9/L</math>; drug-related platelet dysfunction or uremia; underlying coagulopathy.</li> </ul> </li> <li>• Wait 12 h after last prophylactic-dose LMWH administration for lumbar puncture or spinal anesthesia.</li> <li>• In case of contraindication, apply physical antithrombotic measures.</li> <li>• Thromboprophylaxis is not required in cancer patients hospitalized exclusively to receive oncologic treatment (except in case of immobilization).</li> </ul>

**Table 1** (Continued)

Question	Background	Suggestions
<b>Initial treatment</b>		
<p>3. Must LMWH dose be modified in cancer patients with acute VTE treated with antiangiogenic drugs?</p>	<ul style="list-style-type: none"> <li>• Most clinical trials assessing antiangiogenic drugs excluded anticoagulated patients.</li> <li>• Indirect information can be obtained from some bevacizumab studies.<sup>25-33</sup></li> </ul>	<ul style="list-style-type: none"> <li>• In general, the LMWH dose should not be modified in patients developing a VTE event while on antiangiogenic treatment.</li> <li>• Special caution is required in case of CNS involvement.</li> <li>• Resumption of the antiangiogenic therapy (if indicated) should be delayed at least 2 wk after starting LMWH.</li> </ul>
<p>4. In patients with CAT requiring surgery or invasive procedure, when should the placement of an inferior vena cava filter be considered?</p>	<ul style="list-style-type: none"> <li>• Results from studies on the use of IVCF in cancer patients with VTE are controversial.<sup>34-40</sup></li> <li>• Consensus exists on its use in patients with PE or DVT when ACG is contraindicated, especially in the first weeks after VTE.<sup>41-44</sup></li> <li>• Concern about early and delayed adverse effects associated with IVCF is increasingly growing.<sup>41,44-47</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Use of IVCF is suggested in cancer patients with acute lower limb proximal DVT/PE, who require a procedure that contraindicates ACG, particularly in the first 2-4 wk after the thrombotic episode.</li> <li>• After the first 2-4 wk, use IVCF only if proximal DVT persists.</li> <li>• While IVCF remains inserted, if possible, administer LMWH at least at prophylactic doses.</li> <li>• Remove IVCF and restart full ACG as soon as the cause that led to placement is resolved.</li> </ul>
<b>Long-term treatment</b>		
<p>5. In patients with CAT that require extended anticoagulant therapy beyond 6 mo, what is the optimal dose if LMWH is maintained?</p>	<ul style="list-style-type: none"> <li>• Guidelines recommend maintaining ACG beyond 6 mo in cases of active cancer and/or ongoing chemotherapy, although optimal drugs and doses are not specified.<sup>44,48</sup></li> <li>• Evidence on LMWH doses to use beyond 6 mo is scarce.</li> <li>• An observational<sup>49</sup> and two single-arm prospective studies, DALTECAN<sup>50</sup> and TICAT (451), provide useful information.</li> <li>• DOACs may be an alternative for selected patients with low risk of gastrointestinal bleeding and drug interactions.<sup>54,56</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Decide dose according to characteristics of patient, of the disease and its treatment, and of the VTE event:             <ul style="list-style-type: none"> <li>- Patient                 <ul style="list-style-type: none"> <li>▪ Full doses: obesity; thrombophilia; immobilization; venous insufficiency; varicose veins and low bleeding risk.</li> <li>▪ Intermediate/prophylactic doses: renal failure or thrombocytopenia, or/and high bleeding risk.</li> </ul> </li> <li>- Tumor                 <ul style="list-style-type: none"> <li>▪ Full doses: metastatic disease or locoregional disease with vessel compression; tumors with high thrombotic risk.</li> <li>▪ Intermediate/prophylactic doses: tumors with lower thrombotic risk.</li> </ul> </li> <li>- VTE event                 <ul style="list-style-type: none"> <li>▪ Full doses: life-threatening symptomatic PE, recurrent VTE, post-thrombotic syndrome.</li> <li>▪ Intermediate/prophylactic doses: incidental PE; isolated LL DVT; CVC-associated thrombosis; recurrent SVT.</li> <li>▪ Dose increased by 25%: VTE recurrence in spite of appropriate LMWH.</li> </ul> </li> </ul> </li> </ul>
<p>6. Should anticoagulant treatment be prolonged beyond 3-6 mo in cancer patients with CVC-DVT, when the central venous line is maintained? Is LMWH prophylaxis indicated in patients with previous CVC-DVT if a new CVC has to be inserted?</p>	<ul style="list-style-type: none"> <li>• Current recommendations are not uniform across different guidelines and not supported by evidence of sufficient quality.<sup>43,44,57-59</sup></li> <li>• If the CVC is maintained beyond the first 3-6 mo of anticoagulation after a CVC-DVT, the scenario could be considered as a VTE secondary to a persistent risk factor.</li> </ul>	<ul style="list-style-type: none"> <li>• After 3-6 mo, if bleeding risk is not high, prolong ACG using intermediate or prophylactic doses of LMWH until CVC removal.</li> <li>• If a new CVC is inserted in a patient with previous history of CVC-DVT, use prophylaxis with LMWH for 30 d. Consider longer periods depending on bleeding risk and patient's preferences.</li> </ul>

(Continued)

Table 1 (Continued)

Question	Background	Suggestions
<b>Treatment of VTE in complex scenarios</b>		
7. How should CAT be treated in cases of primary or secondary central nervous system involvement?	<ul style="list-style-type: none"> <li>• Anticoagulation is effective, and usually well tolerated, in patients with gliomas<sup>62</sup> or cerebral metastases.<sup>63</sup> Some data favor treatment modifications under certain circumstances.</li> <li>• Brainstem hemorrhages are particularly serious.</li> </ul>	<ul style="list-style-type: none"> <li>• In general, use LMWH according to standard guidelines.</li> <li>• The following exceptions are made: <ul style="list-style-type: none"> <li>- In secondary CNS involvement due to melanoma or kidney cancer, if VTE is not severe, reduce LMWH dose by 25–50%.</li> <li>- In patients with brainstem glioma, initially reduce LMWH dose by 25–50%, until local control of the disease is achieved.</li> </ul> </li> </ul>
8. Should incidental splanchnic venous thrombosis be treated?	<ul style="list-style-type: none"> <li>• In a prospective registry of splanchnic VT, not limited to cancer patients, recurrences were more frequent in male patients with incidental thrombosis and shorter time on ACG.<sup>66,67</sup></li> <li>• While on anticoagulant treatment, in patients with incidentally diagnosed splanchnic VT, the rate of major bleeding did not exceed that of recurrent thrombosis, although specific results in cancer patients are unknown.</li> <li>• Individualization is suggested according to chronic/nonchronic nature of thrombus.<sup>42,68</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Start ACG treatment unless there is a formal contraindication.</li> <li>• Individualize in case of: <ul style="list-style-type: none"> <li>- Data suggestive of chronic thrombosis.</li> <li>- Isolated thrombosis of intrahepatic portal segmental branch.</li> </ul> </li> <li>• ACG should be maintained for at least 3 mo.</li> </ul>
9. In cancer patients with acute VTE, what platelet count threshold would imply modifications in the LMWH dose? Can platelet transfusions avoid LMWH dose reductions?	<ul style="list-style-type: none"> <li>• Full-dose ACG is accepted with platelet counts <math>&gt;50 \times 10^9/L</math>. Controversy arises with lower values.</li> <li>• There is reticence about recommendation of transfusing platelets to reach <math>&gt;50 \times 10^9/L</math> to maintain therapeutic LMWH doses [ISTH and Canadian Consensus<sup>41,69,74</sup>]: it is complex and is associated with risk of adverse effects.<sup>70,71</sup></li> <li>• Others support dynamic strategies of ACG dose reduction,<sup>73</sup> or platelet transfusion with lower thresholds (<math>&lt;20 \times 10^9/L</math>).<sup>71</sup></li> </ul>	<ul style="list-style-type: none"> <li>• With counts <math>\geq 50 \times 10^9/L</math>, maintain full doses of LMWH.</li> <li>• With counts between 20 and <math>50 \times 10^9/L</math>, reduce LMWH 50%.</li> <li>• With counts <math>\leq 20 \times 10^9/L</math> <ul style="list-style-type: none"> <li>- If <math>&gt;30</math> d since VTE diagnosis, withhold ACG.</li> <li>- If <math>&lt;30</math> d since VTE diagnosis, transfuse platelets to maintain counts <math>&gt;20 \times 10^9/L</math>, and use intermediate LMWH doses.</li> </ul> </li> <li>• Consider IVCF in the acute phase of VTE (especially when thrombocytopenia is thought to last <math>&gt;5</math> d) in: <ul style="list-style-type: none"> <li>- Patients with counts <math>\leq 20 \times 10^9/L</math>.</li> <li>- Patients with counts 20–<math>50 \times 10^9/L</math> and low cardiopulmonary reserve.</li> </ul> </li> </ul>
10. In patients with acute CAT requiring anticoagulant treatment and who were under antiplatelet therapy, when should the latter be maintained?	<ul style="list-style-type: none"> <li>• ACG with VKA prevents coronary disease progression, and ischemic stroke in AF patients.<sup>76</sup></li> <li>• The combined use of antiplatelet drugs with ACG treatment does not always improve ischemic events prevention and increases hemorrhagic risk.<sup>77,78</sup></li> <li>• The use of VKA together with two antiplatelet drugs involves a high hemorrhagic risk, but may be justified for short periods in situations of high thrombotic risk.<sup>79</sup></li> <li>• In patients with thrombosis associated with a MPN, the benefit of combined aspirin plus ACG is probably outweighed by the increased risk of bleeding.<sup>81–83</sup></li> </ul>	<ul style="list-style-type: none"> <li>• In cancer patients on ACG treatment for VTE, maintain antiplatelet drugs only in exceptional situations of markedly elevated risk of coronary events.</li> <li>• Maintenance of antiplatelet treatment in patients who are going to start anticoagulant therapy for CAT is justified in case of recent (<math>&lt;1</math> y) ACS event or placement of a coronary stent.</li> <li>• In patients with acute CAT carrying stents in other vascular beds, maintenance of antiplatelet treatment while on anticoagulant therapy should be decided in a case-by-case basis.</li> </ul>
<b>Laboratory</b>		
11. In cancer patients treated with LMWH, when should anti-factor Xa activity be monitored?	<ul style="list-style-type: none"> <li>• In studies with LMWH for the treatment of CAT, no relevant accumulation over time was observed.<sup>55,84,85</sup></li> <li>• However, there are situations where pharmacokinetics of LMWH may be affected.<sup>87</sup></li> <li>• Thrombocytopenia does not alter LMWH pharmacokinetics.</li> </ul>	<ul style="list-style-type: none"> <li>• In patients with CAT, routine monitoring of anti-Xa activity is not required.</li> <li>• In cases of creatinine clearance <math>&lt;30</math> mL/min, extreme body weight, or pregnancy, LMWH dose adjustment according to peak anti-Xa activity is suggested.</li> </ul>

**Table 1** (Continued)

Question	Background	Suggestions
	<ul style="list-style-type: none"> <li>An association between anti-Xa activity and either clinical efficacy or hemorrhagic risk has not been demonstrated.<sup>89</sup></li> </ul>	<ul style="list-style-type: none"> <li>Monitoring anti-Xa in patients with thrombocytopenia or with other hemorrhagic risk factors is not suggested. The LMWH dose should not rely on this variable.</li> <li>Monitoring anti-Xa activity is not suggested for prophylactic doses of LMWH.</li> </ul>
12. Should thrombophilia study be performed in patients with CAT?	<ul style="list-style-type: none"> <li>Thrombophilic abnormalities have little influence on clinical decisions on ACG for VTE.<sup>43,91,92</sup></li> <li>In the cancer setting, initial ACG treatment for CAT is similar in patients with thrombophilia, and ACG duration is mainly influenced by cancer status.<sup>42–44,91</sup></li> </ul>	<ul style="list-style-type: none"> <li>In patients with CAT, do not routinely investigate the presence of thrombophilia.</li> </ul>

Abbreviations: ACG, anticoagulation/anticoagulant; ACS, acute coronary syndrome; AF, atrial fibrillation; anti-Xa, anti-factor Xa; CNS, central nervous system; CAT, cancer-associated thrombosis; CVC, central venous catheter; CVC-DVT, deep venous thrombosis associated with central venous catheter; DVT, deep venous thrombosis; ISTH, International Society on Thrombosis and Haemostasis; IVC, inferior vena cava filter; LL, lower limbs; LMWH, low-molecular-weight heparin(s); MPN, myeloproliferative neoplasm; PE, pulmonary embolism; SEMI, Spanish Society of Internal Medicine; SEOM, Spanish Society of Medical Oncology; SETH, Spanish Society of Thrombosis and Haemostasis; SVT, superficial vein thrombosis; VKA, vitamin K antagonists; VTE, venous thromboembolic event/venous thromboembolism.

Notes: Twelve experts from the SETH, SEOM, and SEMI formed four teams of three, which included one member of each society. Each team elaborated initial consensus statements on three different questions. After a subsequent discussion with the participation of the whole panel of experts, a final consensus was reached for each one of the 12 proposed questions, all of which are controversial because of the scarce solid literature available about them.

characteristics of the COMPASS risk assessment model was 0.85. The ONKO-TEV score showed an AUC at 3 months of 71.9 versus 57.9% with the Khorana score. However, validation is still required.

- The addition of some biomarkers such as D-dimer or genomic risk profiles may help improve the usefulness of VTE risk scores.<sup>15,16</sup>
- A different strategy, based on tumor-specific assessment models, has been developed. The Throly score, developed for patients with lymphomas, showed high negative predictive value (NPV; 97%), although the positive predictive value (PPV) was 15%. Another new risk model for prediction of VTE in gynecological cancer patients has also shown promising results.<sup>17,18</sup>

Currently, routine thromboprophylaxis in ambulatory cancer patients is not recommended. Better tools to stratify VTE risk are needed to favor a primary prevention strategy in ambulatory cancer patients.

**Suggestions**

- Assessment of thrombotic risk in cancer patients on ambulatory treatment is suggested, with the purpose of identifying those who would, theoretically, benefit more from antithrombotic prophylaxis.
- Although Khorana’s risk score is the only validated prediction model, it should not be the only tool used to select the patients who will receive ambulatory antithrombotic prophylaxis. Bleeding risk factors also have to be considered.
- New predictive models including biomarkers such as D-dimer or genomic risk profile, or tumor-specific scores, may help improve risk stratification.

**Question 2: In Cancer Patients Who Are Hospitalized for an Acute Medical Illness, When Is Pharmacological Antithrombotic Prophylaxis Contraindicated?**

**Background**

Current guidelines agree that cancer patients who are hospitalized for any complication related to their clinical condition are at very high VTE risk, recommending pharmacologic prophylaxis with low-molecular-weight heparin (LMWH), unless contraindicated.<sup>1–5</sup> However, studies that specifically address the risk–benefit of thromboprophylaxis in cancer inpatients are lacking. In fact, recommendations are based on the results of trials whose cohorts consisted of heterogeneous groups of medical patients, among which cancer patients were underrepresented (5–15%).<sup>19–23</sup> A recent meta-analysis restricted to the cancer subgroup of the aforementioned studies did not confirm a positive effect of thromboprophylaxis.<sup>24</sup>

On the other hand, cancer patients also exhibit an increased bleeding tendency and are considered as a high-risk population for hemorrhages. Therefore, a careful benefit–risk balance for each individual patient is advisable. Although validated tools to assess bleeding risk in cancer patients are lacking, several circumstances imply a contraindication for pharmacologic thromboprophylaxis.

**Suggestions**

- Settings where primary thromboprophylaxis with LMWH is contraindicated for cancer inpatients:
  - Absolute contraindications:
    - Recent bleeding in the central nervous system.
    - Active major bleeding.
    - Thrombocytopenia  $<20 \times 10^9/L$ .

- Relative contraindications:
  - Clinically relevant chronic bleeding, lasting for more than 48 hours.
  - Initial period of postneurosurgery (48–72 hours).
  - High bleeding risk–associated spinal or intracranial lesions (e.g., melanoma or kidney metastases).
  - High risk of falls.
  - Thrombocytopenia  $20 \times 10^9$  to  $50 \times 10^9/L$ .
  - Severe platelet dysfunction.
  - Underlying coagulopathy.
  - Lumbar puncture or spinal anesthesia (procedures should be delayed 12 hours after last prophylactic LMWH dose).
- When pharmacological thromboprophylaxis is contraindicated, alternative use of mechanical measures is suggested.
- Thromboprophylaxis with LMWH is not necessary in patients admitted to hospital for scheduled oncological treatment who are not immobilized.

### Question 3: Must the LMWH Dose Be Modified in Cancer Patients with Acute VTE Receiving Antiangiogenic Drugs?

#### Background

Patients on anticoagulant therapy were explicitly excluded from most clinical studies with antiangiogenic drugs.<sup>25,26</sup> Furthermore, in those studies that allowed participation of anticoagulated patients, vitamin K antagonists (VKA) instead of LMWH (drug of choice for CAT treatment) were mostly used. Certain evidence arises from several clinical trials evaluating bevacizumab:

- Observational prospective or phase IV studies.

The BEAT<sup>27</sup> and the BRITe<sup>28</sup> studies provided comparative analyses on the incidence of severe bleeding (SB [grades 3–5]) between anticoagulated and non-anticoagulated bevacizumab-treated patients. Both studies showed higher SB rates among anticoagulated patients (4.3 vs. 2.4% in BEAT and 6.0 vs. 2.2% in BRITe, respectively). In contrast, in the SAIL study the SB rate in patients under anticoagulant therapy was null, compared with 4% in the overall cohort.<sup>29</sup>

- Clinical trials allowing anticoagulant therapy.

In the pivotal trial, the proportion of patients who maintained the study treatment after suffering a VTE event and starting anticoagulant therapy was 6.5% in the bevacizumab arm and 3.4% in the placebo arm.<sup>26</sup> SB episodes were experienced by 3.8 and 6.7% of those patients, respectively.<sup>30</sup> On the contrary, in the AVADO study, the incidence of SB among anticoagulated bevacizumab-treated patients was 5% compared with 0% in anticoagulated placebo-treated patients, and 1.2% in the bevacizumab group that did not receive anticoagulants.<sup>31</sup>

- Systematic reviews.

Data from 3,201 patients were collected.<sup>32</sup> Patients were allowed to continue with the study medication after an acute

VTE event if the following criteria were fulfilled: absence of active bleeding, maintenance of stable anticoagulation for at least 2 weeks, and, in two of the three studies, absence of major vessel invasion. The SB rates, obtained from 194 anticoagulated patients, were similar in those treated with either bevacizumab or placebo (4.1 vs. 4.2%, respectively).

- Meta-analysis.

Finally, a meta-analysis including 10 studies and 6,055 bevacizumab-treated patients found that 10.5% of those who suffered a VTE and started anticoagulant therapy did not discontinue the antiangiogenic treatment.<sup>33</sup> In this subgroup, the bleeding rate was 1.9% (SB in 0.2% of cases), versus 1.2% among patients who did not require anticoagulant treatment.

#### Suggestions

- In the absence of bleeding, a reduction of the LMWH dose to be administered to a patient developing an acute VTE event while on antiangiogenic treatment is not suggested. Special caution is required in patients with central nervous system involvement.
- Resumption of the antiangiogenic therapy, after starting anticoagulant therapy for an acute VTE event, should be delayed for a reasonable period of 2 weeks to check the absence of any bleeding complication before adding any further risk factor. In case of life-threatening VTE, resumption of the antiangiogenic therapy is not recommended.

### Question 4: In Patients with CAT Requiring Surgery or an Invasive Procedure, When Should the Placement of an Inferior Vena Cava Filter Be Considered?

#### Background

The evidence supporting the use of inferior vena cava filters (IVCFs) in cancer patients is scarce. While some studies suggested that IVCFs are safe and effective, others found an increased risk of recurrent deep venous thrombosis (DVT; indeed, the cancer-related hypercoagulability is not corrected by the IVCF), as well as no benefit regarding pulmonary embolism (PE) incidence or short-term mortality.<sup>34–40</sup> Nevertheless, most guidelines recommend the use of IVCF in cancer patients with proximal acute DVT or PE when anticoagulant therapy is contraindicated.<sup>41–44</sup> Such is the case of major surgery or invasive procedures. Lumbar puncture, spinal anesthesia, or epidural catheter placement are considered as special procedures.<sup>42</sup> The use of IVCF would be particularly useful within the first 2 to 4 weeks after the acute thrombotic event due to the high recurrence risk in that particular period.<sup>45</sup> The use of IVCF is not clearly supported in other scenarios.<sup>45–47</sup> Furthermore, other potential adverse events associated with its use, such as placement or removal complications, migration, breakage, or thrombosis of the device, should be taken into account.<sup>41,44–47</sup>

Moreover, anticoagulation should be restarted, and the IVCF removed, once the contingency that led to its placement is resolved. The strategy of IVCF removal should be defined prior to filter insertion.<sup>41,43–46</sup>



## Suggestions

- The use of a retrievable IVCF is suggested in cancer patients with acute proximal lower limb DVT or PE who require surgery or an invasive procedure that contraindicates anticoagulant therapy, particularly within the first 2 to 4 weeks after diagnosis. After 4 weeks from the diagnosis of the thrombotic episode, the placement of an IVCF is suggested in case of persistent proximal DVT (femoral or iliac veins).
- While the IVCF remains placed, the use of (at least) prophylactic LMWH, if not contraindicated by the bleeding risk, is suggested.
- Full anticoagulant therapy should be restarted and IVCF removed as soon as the cause leading to the placement of the filter is resolved.

### Question 5: In Patients with CAT Who Require Extended Anticoagulant Therapy beyond Six Months, What Is the Optimal Dose if LMWH Is Maintained?

#### Background

After completing 6 months of anticoagulant therapy for CAT, current clinical guidelines recommend to continue anticoagulation in case of active cancer and/or ongoing chemotherapy due to the high risk of recurrent VTE. However, since the observation period in available randomized trials comparing VKA and LMWH in this setting lasted 6 months, the drug/dose of choice for extended therapy is a matter of debate.<sup>44,48</sup>

Useful data are provided by a subgroup analysis of an observational study,<sup>49</sup> and two single-arm prospective studies designed to evaluate LMWH safety over a 12-month period: the DALTECAN study,<sup>50</sup> in which dalteparin dose was reduced after the first month of treatment, and the TICAT study,<sup>51</sup> in which tinzaparin was used at full dose throughout the study.

Until stronger evidence becomes available, the dose of LMWH for extended therapy beyond 6 months should be tailored considering several issues: severity of VTE, cancer type and extension, ongoing anticancer therapies, bleeding risk, and patients' characteristics and preferences, which may change over time.<sup>52,53</sup> Indeed, intrinsic differences in the dosing of the various LMWH must be taken into account (as mentioned earlier, the standard therapeutic dose of dalteparin after the first month of treatment is 150 IU/Kg instead of 200 IU/Kg, while for the other molecules the full dose is maintained during the 6-month anticoagulation period).

Other options for extended therapy are VKA (although maintaining therapeutic INR ranges may be difficult in cancer patients under active antineoplastic therapy) and direct oral anticoagulants (DOACs). Very recently, two randomized clinical trials in patients with CAT have compared the efficacy and safety of edoxaban and rivaroxaban, direct factor Xa inhibitors, versus dalteparin using the CLOT trial scheme (200 UI/kg/day the first month, 150 UI/kg/day afterward)<sup>54-56</sup> for a minimum observation period of 6 months. In the Hokusai-VTE cancer study, no significant differences were observed in the rate of the primary composite endpoint (recurrent VTE and/or major bleeding), albeit patients in the

edoxaban arm had a lower rate of VTE recurrence and a higher rate of major bleeding, especially gastrointestinal bleeding.<sup>54</sup> Similarly, the 6-month cumulative VTE recurrence rate was higher with dalteparin compared with rivaroxaban, although major bleeding was increased in the rivaroxaban arm.<sup>56</sup> The results of other ongoing studies may confirm a role of DOACs as an alternative for CAT extended therapy. However, current restraints by health authorities limit its use in patients with VTE in Spain and other countries, making LMWH the drug of choice for extended treatment of CAT.

#### Suggestions

- When LMWH treatment for CAT is to be prolonged beyond 6 months, the characteristics of each individual patient, of the underlying malignancy and its treatment and of the index VTE, should be considered to decide the optimal dose.
  - Table 2 summarizes useful criteria to guide decisions.

### Question 6: Should Anticoagulant Treatment Be Prolonged Beyond 3–6 Months in Cancer Patients with Catheter-Related DVT (CVC-DVT), When the Central Venous Line Is Maintained? Is LMWH Prophylaxis Indicated in Patients with previous CVC-DVT if a New CVC Is Needed?

#### Background

Some guidelines have addressed the initial management of central venous catheter (CVC)-DVT in cancer patients, although the strength of the evidence is limited.<sup>43,44,57-59</sup> In fact, the use of LMWH in this setting relies on general clinical trials of CAT. In general, anticoagulation for a minimum period of 3 months is recommended, even if the CVC is removed earlier. However, the CVC can be kept in place as long as it is functional, not infected, and DVT-related symptoms improve adequately.

In certain sense, if the CVC is maintained (or a new CVC is placed) beyond the first 3 to 6 months of anticoagulation for a CVC-DVT episode, the scenario could be comparable to a provoked VTE with a persistent risk factor. Therefore, the risk of recurrent thrombosis without anticoagulant treatment would be relatively high. In a study from the RIETE registry, the incidence of recurrent thrombosis after discontinuation of anticoagulant therapy in patients with CVC-DVT was 3.4 events/100 patient-years, but the proportion of patients in whom the central line remained inserted was not specified.<sup>60</sup> Another retrospective study suggested that after 3 months of LMWH, anticoagulation can safely be discontinued in patients with CVC-DVT when cancer is in remission and catheter is removed.<sup>61</sup> Two late recurrent VTE events (lower limb DVT) were observed in 16 patients in whom the central line was kept and continued anticoagulation beyond 3 months. In both cases, the patients were receiving only prophylactic doses of LMWH. No recurrent upper extremity DVT was observed in this group. Given the low number of patients and events, no definite conclusions regarding the optimal dose of LMWH for secondary prevention in this scenario can be derived.

**Table 2** Criteria to decide LMWH dose when anticoagulant treatment for CAT is prolonged beyond the first 6 mo

	Full-dose LMWH <sup>a</sup>	Intermediate or prophylactic LMWH dose	LMWH dose increased 25%
VTE event	<ul style="list-style-type: none"> <li>Life-threatening symptomatic PE</li> </ul>	<ul style="list-style-type: none"> <li>Incidental PE</li> <li>Isolated lower limb DVT</li> <li>Catheter-associated thrombosis</li> </ul>	<ul style="list-style-type: none"> <li>VTE recurrence in spite of full-dose LMWH</li> </ul>
Patient characteristics	<ul style="list-style-type: none"> <li>Obesity</li> <li>Immobilization</li> <li>Thrombophilia</li> <li>Venous insufficiency, varicose veins, postthrombotic syndrome</li> </ul>	<ul style="list-style-type: none"> <li>Renal impairment</li> <li>Thrombocytopenia</li> </ul>	
Neoplasm	<ul style="list-style-type: none"> <li>Metastatic disease</li> <li>Tumor vessel compression</li> <li>High thrombotic risk cancer: lung, pancreas, gastroesophageal</li> </ul>	<ul style="list-style-type: none"> <li>Cancers with lower thrombotic risk: breast, prostate</li> </ul>	
Cancer treatment	<ul style="list-style-type: none"> <li>Chemotherapy</li> <li>Erythropoietin</li> <li>Hormone therapy</li> </ul>	<ul style="list-style-type: none"> <li>Immunotherapy</li> <li>Targeted therapies</li> </ul>	
Bleeding risk	Low: <ul style="list-style-type: none"> <li>No bleeding history</li> </ul>	High: <ul style="list-style-type: none"> <li>Previous tumor bleeding</li> <li>Previous bleeding history due to any other cause</li> <li>Treatment with antiangiogenic drugs</li> <li>Concomitant treatment with antiplatelet drugs</li> </ul>	

Abbreviations: CAT, cancer-associated thrombosis; DVT, deep venous thrombosis; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; SVT, superficial vein thrombosis; VTE, venous thromboembolism.

<sup>a</sup>For dalteparin, full doses after the first month of treatment, according to DALTECAN and CLOT studies, is 150 IU/kg/24 hours.<sup>47,52</sup>

### Suggestions

- When the CVC is maintained after having completed 3 to 6 months of LMWH treatment due to a CVC-DVT event in a cancer patient, prolongation of LMWH therapy using intermediate or prophylactic doses is suggested. Treatment should be continued until CVC removal, as long as patient's bleeding risk is not high.
- In cancer patients with previous CVC-DVT history who require a new CVC, LMWH prophylaxis for at least 30 days after placement is suggested. Prophylaxis for a longer period, as long as the CVC remains inserted, may be considered, although patient's bleeding risk and preferences should also be valued.

### Question 7: How Should CAT Be Treated in Patients with Primary or Secondary Central Nervous System Involvement?

#### Background

Anticoagulation is effective, and usually well tolerated, in patients with gliomas<sup>62</sup> or cerebral metastases.<sup>63</sup> Nevertheless, some data may favor treatment modifications under certain circumstances:

- A retrospective study analyzed the outcomes of 364 patients with CAT, half of them with primary or metastatic brain tumors, for a median time of 6 months.<sup>64</sup>

There were no differences between groups in the incidence of VTE recurrence (11.0 vs. 13.5 cases per 100 patients-year,  $p = 0.26$ ) or major bleeding (8.9 vs. 6.0 cases per 100 patients-year,  $p = 0.80$ ).

- Another retrospective study included 293 patients with cerebral metastases, 104 of who received therapeutic doses of enoxaparin due to acute VTE.<sup>63</sup> There were no differences in the 1-year incidence of cerebral hemorrhage compared with non-anticoagulated patients (total bleeding: 44 vs. 37%, respectively,  $p = 0.13$ ). The risk of intracranial hemorrhage was fourfold higher for melanoma or kidney cancer when compared with lung cancer, although the increased risk was not associated with enoxaparin use.
- A meta-analysis with 1,480 patients with central nervous system (CNS) malignancies compared the risk of intracranial hemorrhage between those who received anticoagulant therapy with LMWH or warfarin, and those who were not treated with anticoagulant drugs.<sup>65</sup> The odds ratio (OR) of intracranial hemorrhage in anticoagulated patients was 2.13 (95% confidence interval [CI]: 1.0–4.56). The risk was not increased in patients with CNS metastases (OR: 1.07, 95% CI: 0.61–1.88), in contrast to those with cerebral glioma (OR: 3.75, 95% CI: 1.42–9.95). However, the higher incidence of intracranial bleeding did not seem to be associated with LMWH use (OR: 0.75, 95% CI: 0.24–2.33).



- Finally, since brainstem hemorrhages are particularly serious, any condition involving such area should be managed cautiously.

### Suggestions

- In general, in the absence of other contraindications, in patients with primary or secondary neoplastic involvement of CNS, standard treatment of CAT with full-dose LMWH according to guidelines is suggested. However, the following exceptions may be considered:
  - In patients with secondary CNS involvement from melanoma or kidney cancer, and especially when the VTE event is not severe, a 25 to 50% reduction of the LMWH dose could be considered.
  - In cases of glioma in the brainstem, a 25 to 50% reduction in LMWH dose is suggested. If disease control with local treatment is achieved, a subsequent LMWH dose increase may be weighed.

### Question 8: Should Incidental Splanchnic Venous Thrombosis Be Treated?

#### Background

The most relevant information comes from a recent international registry promoted by the ISTH, although the study was not limited to cancer patients.<sup>66,67</sup> A total of 604 splanchnic venous thromboses (VTs), 177 (30%) of them incidental, were consecutively included. Sixty-two of 177 (35%) incidental splanchnic VTs were associated with nonhematologic cancer. In this latter group, one major bleeding event (1.2 cases per 100 patients-year) and seven thrombotic recurrences (8.1 cases per 100 patients-year) were observed during follow-up.<sup>67</sup> However, additional analyses may be useful for the decision-making process:

- The probability of being administered anticoagulant treatment was lower in both, patients with cancer and patients with incidental thrombosis.<sup>67</sup>
- Treatments given to patients with incidental splanchnic VT were markedly heterogeneous regarding drug and duration. Patterns ranged from 6 months with parenteral anticoagulants, especially LMWH, to 24 months with oral VKA.<sup>67</sup>
- Patients with thrombocytopenia (platelet count  $\leq 100 \times 10^9/L$ ) were less prone to receive anticoagulant treatment, and showed the highest rate of major bleeding.<sup>67</sup> A thrombotic recurrent event was more frequently seen in male patients with incidental thrombosis and shorter duration of the anticoagulant therapy.<sup>66</sup>
- Regardless of cancer, the rate of recurrences during anticoagulant treatment was similar in patients with symptomatic or incidental splanchnic VT.<sup>67</sup>
- While on anticoagulant treatment, in patients with incidentally diagnosed splanchnic VT, the rate of major bleeding did not exceed that of recurrent thrombosis, although specific results in cancer patients are unknown.<sup>67</sup>

In another recent study from the RIETE group including 521 patients with splanchnic VT, 309 (59%) incidental, most

of them received anticoagulant therapy.<sup>68</sup> Compared with patients with symptomatic splanchnic VT, those with incidental splanchnic VT had a nonsignificantly higher risk of symptomatic VTE recurrence (hazard ratio [HR]: 2.04; 95% CI: 0.71–5.88) and a similar risk of major bleeding (HR: 1.12; 95% CI: 0.47–2.63). Active cancer was associated with an increased risk of recurrence (HR: 3.06; 95% CI: 1.14–8.17).

Although the quality of the evidence is low, international guidelines suggest that in cancer patients with incidental splanchnic VT, anticoagulant treatment should be considered in a case-by-case basis, taking into account clinical data suggestive of chronic thrombosis, such as collateral circulation or portal cavernomatosis.<sup>42,58</sup> No recommendation about the need of an upper gastrointestinal endoscopy to look for esophageal varices that could be treated before starting anticoagulant therapy is made. There are no specific recommendations according to the splanchnic vein involved either. Nevertheless, anticoagulant therapy seems more warranted in patients with portal thrombosis candidates for liver transplantation, or in those with superior mesenteric vein thrombosis involving a large intestinal surface area.

### Suggestions

- Unless contraindicated, in cancer patients diagnosed with incidental splanchnic VT, starting anticoagulant treatment is suggested.
- Treatment should be individualized in cases with clinical data suggesting chronic thrombosis, as well as in cases of isolated thrombosis of an intrahepatic portal segmental branch.
- Anticoagulant treatment should be maintained for at least 3 months.

### Question 9: In Cancer Patients with Acute VTE, What Platelet Count Threshold Would Imply Modifications in the LMWH Dose? Can Platelet Transfusions Avoid LMWH Dose Reductions?

#### Background

Full-dose anticoagulation with platelet counts higher than  $50 \times 10^9/L$  is universally accepted, also in the context of CAT. However, management with lower counts is controversial. Both, the ISTH in 2013 and the 2015 Canadian Consensus Guidelines recommended the following<sup>41,69</sup>:

- For VTE diagnosed more than 30 days ago, anticoagulant dose should be reduced in case of platelet counts lower than  $50 \times 10^9/L$ .
- In the acute phase of VTE (i.e., the first 30 days since onset), transfuse platelets to reach counts higher than  $50 \times 10^9/L$ , and anticoagulation should be kept at full therapeutic doses. This recommendation is based on the higher risk of recurrence during the first month after VTE diagnosis.

However, there are some concerns regarding this last recommendation<sup>70,71</sup>:

- First, sustaining an intensive platelet transfusion program to reach and maintain the threshold of  $50 \times 10^9/L$  is not easy and in many cases results unsuccessful.

- Second, transfusion may imply some safety concerns. In fact, an observational study showed that platelet transfusion aimed to reach counts greater than  $50 \times 10^9/L$  to maintain anticoagulation, was not only unable to reduce the hemorrhagic risk but was associated with frequent transfusion-related adverse effects.<sup>72</sup>

By contrast, some studies assessed other alternatives:

- A recent observational study performed at the Memorial Sloan Kettering Cancer Center validated a dynamic strategy of enoxaparin dose reduction with the purpose of avoiding platelet transfusion. Such practice could be implemented at any VTE period, even in the first month.<sup>73</sup> In this study, therapeutic doses of enoxaparin were administered in case of platelet counts greater than  $50 \times 10^9/L$ , while half-dose was used with platelet counts between 25 and  $50 \times 10^9/L$ . Anticoagulant treatment was withheld if counts were less than  $25 \times 10^9/L$ . An IVCF was placed in 21 out of the 99 patients who participated in the study.
- Likewise, an intermediate strategy has also been proposed, which encourages platelet transfusion albeit with a lower threshold,  $20 \times 10^9/L$ .<sup>71</sup>

In the very recent update of the ISTH guidelines, the experts suggest a dose modification strategy using 50% or prophylactic-dose LMWH for patients with platelet count of 25 to  $50 \times 10^9/L$  and acute CAT with lower risk of thrombus progression (i.e., distal DVT, incidental subsegmental PE, or CVC-DVT). In case of higher risk of thrombus progression, platelet transfusion to maintain a platelet count over 40 to  $50 \times 10^9/L$  and use of full-dose LMWH are recommended.<sup>74</sup>

Finally, in a novel study from the RIETE registry (R. Lecumberri, MD, PhD, May 2018, unpublished data), the use of lower doses of LMWH in patients with acute CAT and severe thrombocytopenia seemed to be effective and safe, leading to low early rates of major bleeding and recurrent VTE, very close to those observed in cancer patients with normal platelet counts, although cancer-related mortality was significantly increased.

### Suggestions

- In case of mild thrombocytopenia (platelet counts  $\geq 50 \times 10^9/L$ ), keeping anticoagulant treatment at full therapeutic doses is suggested.
- In case of thrombocytopenia with counts lower than  $50 \times 10^9/L$  but higher than  $20 \times 10^9/L$ , a 50% reduction in the LMWH dose is suggested.
- In case of thrombocytopenia with counts equal or lower than  $20 \times 10^9/L$ :
  - If VTE was diagnosed more than 30 days ago, temporary interruption of anticoagulant treatment is suggested.
  - If VTE diagnosis was less than 30 days ago (acute VTE), platelet transfusion aimed to keep counts above  $20 \times 10^9/L$ , and anticoagulation using intermediate LMWH doses, is suggested.
- In the acute phase of VTE, placement of an IVCF can be considered in case of platelet counts equal or lower than  $20 \times 10^9/L$  or in patients with low cardiopulmonary

reserve and counts ranging between 20 and  $50 \times 10^9/L$ , especially if thrombocytopenia is anticipated to continue for more than 5 to 7 days.

### Question 10: In Patients with CAT Requiring Anticoagulant Treatment and Who Were under Antiplatelet Therapy, When Should the Latter Be Maintained?

#### Background

Evidence on the need of maintaining or stopping antiplatelet therapy in patients with CAT is lacking. However, some data from atrial fibrillation (AF) and coronary artery disease patients may be useful:

- The use of VKA to treat a VTE event in patients with cancer is associated with a 3- to 6-fold higher hemorrhagic risk than that observed in patients without cancer.<sup>75</sup>
- Many randomized clinical trials have shown that LMWH is safe and effective in acute coronary syndrome (ACS) without ST elevation.<sup>76</sup>
- In AF patients who have stable coronary disease and for whom anticoagulation is indicated, oral anticoagulation therapy (mainly VKA) protects against ischemic stroke and coronary events.<sup>77</sup>
- In AF patients who have stable coronary disease, the combination of VKA and acetylsalicylic acid (ASA), compared with VKA alone, does not reduce the risk of stroke or acute myocardial infarction but increases the risk of severe bleeding by 1.5- to 2-fold.<sup>78</sup>
- Adding clopidogrel to the combination of warfarin and ASA in patients who have suffered an ACS markedly increases the rate of severe hemorrhage (4.6% at 30 days and 10.3% at 6–12 months).<sup>79</sup>
- In patients treated for an ACS and in those who have undergone the placement of a coronary stent, the triple therapy consisting of oral anticoagulation, clopidogrel, and aspirin seems to be justified during a limited period.<sup>80</sup> In patients with high bleeding risk, the triple therapy might be limited to the first month after the ACS, and be followed by double therapy (VKA together with ASA or clopidogrel) for up to 1 year.

On the other hand, in the field of myeloproliferative neoplasms, both arterial and venous thrombotic complications are frequent. ASA is frequently used as primary prophylaxis or as secondary prophylaxis after an arterial event. In spite of the benefit of aspirin in reducing thrombotic complications, this benefit is probably outweighed by the increase of bleeding risk due to the association of ASA plus anticoagulation in comparison to anticoagulants alone.<sup>81–83</sup>

#### Suggestions

- Since anticoagulation at therapeutic doses is effective to prevent coronary disease progression, and the addition of antiplatelet drugs increases the hemorrhagic risk, the indication of combined antiplatelet plus anticoagulant treatment for CAT should be limited to exceptional situations involving a very high risk of coronary event.

- Maintenance of antiplatelet therapy in patients who are going to start anticoagulant therapy for CAT is justified in case of recent (<1 year) ACS event or placement of a coronary stent.
- In patients with CAT carrying stents in other vascular beds, maintenance of antiplatelet treatment while on anticoagulant therapy should be decided in a case-by-case basis.

### Question 11: In Cancer Patients Treated with LMWH, When Should Anti-factor Xa Activity Be Monitored?

#### Background

In the pivotal studies comparing LMWH versus VKA in CAT, body weight-adjusted LMWH doses were used.<sup>55,84,85</sup> Data from those studies ruled out a significant LMWH accumulation over time, since anti-factor Xa activity (anti-Xa) remained stable.<sup>86</sup> Therefore, in spite of the higher risk of recurrence and bleeding in cancer patients, there is no evidence to support routine monitoring of anti-Xa activity to adjust LMWH dose.

- However, patients with severe renal failure (creatinine clearance <30 mL/min) were excluded from those clinical trials. Clinical practice guidelines suggest monitoring anti-Xa activity when using therapeutic doses of LMWH in patients with severe renal impairment, and also consider initial dose reduction when using enoxaparin or bempiparin.<sup>87</sup>
- Due to variations in drug distribution, the suitability of monitoring anti-Xa activity in patients with extreme body weight and pregnant women has also been suggested.<sup>87</sup>
- Additionally, monitoring anti-Xa activity in high bleeding risk scenarios, for instance, patients with thrombocytopenia, has also been proposed.<sup>88</sup> However, pharmacokinetics of LMWH would not be influenced under these conditions. The same applies to patients who have suffered a recurrent event in spite of treatment with LMWH. An empirical dose increase is recommended, although monitoring of anti-Xa activity might help in optimizing treatment.
- Importantly, the association between anti-Xa activity and either clinical efficacy or bleeding risk has not been undoubtedly demonstrated.<sup>89</sup> Therefore, in the earlier two mentioned scenarios, decisions on LMWH dose should not rely on anti-Xa assessment only.

Finally, the goals of anti-Xa activity for the different LMWH molecules have been retrospectively established. When LMWH is administered in a once-daily regimen, the goal of peak anti-Xa activity is generally around 1 IU/mL.

#### Suggestions

- In patients with CAT, routine monitoring of anti-Xa activity is not required to adjust LMWH dose.
- Renal function should be assessed in patients receiving LMWH at therapeutic doses. If creatinine clearance is less than 30 mL/min, LMWH dose adjustment according to peak anti-Xa activity is suggested (sample withdrawn 4 hours after subcutaneous LMWH administration). Repeated monitoring over time is advisable.

- Monitoring anti-Xa activity in patients with extreme body weight (after several days of treatment) and in pregnant women (once per trimester) is suggested.
- Monitoring anti-Xa in patients with thrombocytopenia or with other hemorrhagic risk factors is not suggested. The LMWH dose should not rely on this variable.
- Monitoring anti-Xa activity is not suggested for prophylactic doses of LMWH.

### Question 12: Should Thrombophilia Study Be Performed in Patients with CAT?

#### Background

Thrombophilia is mainly characterized by VTE at early ages (40–50 years), unprovoked events, or triggered by weak stimuli, recurrences, thrombosis at unusual sites, or strong family history of VTE.<sup>90</sup> The term “hereditary thrombophilia” usually includes deficiency of natural anticoagulants (antithrombin, protein C, protein S), factor V Leiden, and prothrombin G20210A mutation, while lupus anticoagulant or antiphospholipid antibodies are considered acquired thrombophilia.<sup>90</sup> The following points summarize some reasoning that does not support the search for these abnormalities in the context of CAT, since the clinical usefulness and benefits of such practice are rather limited or nonexistent.

- VTE management is generally guided by the clinical features of the event. Thrombophilic abnormalities do not usually change clinical decisions, except for antiphospholipid syndrome and antithrombin deficiency, associated with high recurrence risk, which may favor indefinite anticoagulant treatment. In fact, the main clinical practice guidelines on VTE management do not consider that thrombophilic abnormalities are relevant for initial treatment or duration of therapy.<sup>43,91,92</sup> Moreover, the selection of patients who would benefit from thrombophilia assessment is under discussion, although identification of thrombophilic abnormalities could influence decisions on anticoagulant treatment duration in patients with recurrent VTE or with strong family history.<sup>93–96</sup>
- Patients with cancer exhibit a higher VTE risk. Although a thrombophilic factor could further increase the risk, VTE management in cancer patients is not influenced by the existence of associated thrombophilia: initial recommended treatment is similar to that used in nonthrombophilic cancer patients with VTE, and duration of therapy is mainly influenced by persistence of cancer and/or active oncologic treatment.<sup>42–44,91</sup>

In sum, the existing literature does not provide evidence to justify, at first, a study of thrombophilia in patients with CAT, and guidelines do not recommend to perform it on a routine basis.

#### Suggestions

- The routine search for thrombophilia in patients with CAT is not recommended.

## Conclusion

VTE is an important and potentially avoidable cause of morbimortality in cancer patients that influences prognosis and quality of life. The variety and complexity of clinical scenarios in this setting explains why many therapeutic decisions remain controversial. This consensus was the result of the interest shown by three scientific societies—namely, SETH, SEOM, and SEMI—in CAT. The applied methodology allowed a multidisciplinary approach to each question, as well as validation of the final statements by a solid critical mass, which is particularly important in the absence of strong scientific evidence. The suggestions presented herein may constitute the bases for clinical decisions in specific complex circumstances, until these can be made leaning on reliable scientific evidence.

### Funding

This work has been performed with an unrestricted grant from Aspen, Leo-Pharma, Laboratorios Farmacéuticos Rovi, and Sanofi.

### Conflicts of Interest

V.P. Advisory board: Daiichi-Sankyo.

E.G. Speaker honoraria: Rovi and Leo Pharma; advisory board: Sanofi, Leo Pharma, and Daiichi-Sankyo.

A.M. Speaker honoraria: Rovi; advisory board: Sanofi, Leo Pharma, and Daiichi-Sankyo.

R.L. Speaker honoraria: Rovi and Boehringer-Ingelheim; advisory board: Sanofi, Leo Pharma, and BMS. Research grant: Rovi.

All other authors declare no relevant conflict of interest associated with this work.

### Acknowledgment

The authors thank Dr. Ramón Montes Díaz for medical writing support.

## References

- Lyman GH, Khorana AA, Kuderer NM, et al; American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol* 2013;31(17):2189–2204
- Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schünemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141(2, Suppl):75–475
- Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. *Ann Oncol* 2011;22(Suppl 6):vi85–vi92
- Farge D, Deboudeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. *J Thromb Haemost* 2013;11(01):56–70
- Muñoz AJ, Viñolas N, Cubedo R, Isla D. SEOM guidelines on thrombosis in cancer patients. *Clin Transl Oncol* 2011;13(08):592–596
- Jimenez-Fonseca P, Carmona-Bayonas A, Calderon C, et al. FOTRO-CAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence. *Clin Transl Oncol* 2017;19(08):997–1009
- Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. *Blood* 2008;111(10):4902–4907
- Mansfield AS, Tafur AJ, Wang CE, Kourelis TV, Wysokinska EM, Yang P. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. *J Thromb Haemost* 2016;14(09):1773–1778
- Chaudhury A, Balakrishnan A, Thai C, et al. Validation of the Khorana score in a large cohort of cancer patients with venous thromboembolism. *Blood* 2016;128:879
- Srikanthan A, Tran B, Beausoleil M, et al. Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy. *J Clin Oncol* 2015;33(06):582–587
- Muñoz Martín AJ, Ortega I, Font C, et al. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. *Br J Cancer* 2018;118(08):1056–1061
- Van Es N, Di Nisio M, Cesarman G, et al. Comparison of risk prediction scores for cancer-associated venous thromboembolism: a prospective cohort study. *Haematologica* 2017;102(09):1494–1501
- Gerotziafas GT, Taher A, Abdel-Razek H, et al; COMPASS–CAT Working Group. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS–Cancer-Associated Thrombosis Study. *Oncologist* 2017;22(10):1222–1231
- Cella CA, Di Minno G, Carlomagno C, et al. Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV Study. *Oncologist* 2017;22(05):601–608
- Pabinger I, van Es N, Heinze G, et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. *Lancet Haematol* 2018;5(07):e289–e298
- Soria JM, López S. [The genetics of thrombosis in cancer]. *Med Clin (Barc)* 2015;144(Suppl 1):26–30
- Antic D, Biljana M, Milic N, et al. Internal and external validation of THROLY (thrombosis lymphoma) score. *Thromb Res* 2018;164(suppl 1):S187
- Norris LA, Abu Saadeh F, Ward M, et al. Development and validation of a risk model for prediction of venous thromboembolism in gynaecological cancer patients. *Thromb Res* 2018;164(suppl 1):S183–S184
- Harenberg J, Roebuck P, Heene DL; The Heparin Study in Internal Medicine Group. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. *Haemostasis* 1996;26(03):127–139
- Lechler E, Schramm W, Flosbach CW; The Prime Study Group. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). *Haemostasis* 1996;26(Suppl 2):49–56
- Samama MM, Cohen AT, Darmon JY, et al; Prophylaxis in Medical Patients with Enoxaparin Study Group. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. *N Engl J Med* 1999;341(11):793–800
- Leizorovicz S, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ; PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. *Circulation* 2004;110(07):874–879
- Cohen AT, Davidson BL, Gallus AS, et al; ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. *BMJ* 2006;332(7537):325–329



- 24 Carrier M, Khorana AA, Moretto P, Le Gal G, Karp R, Zwicker JI. Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. *Am J Med* 2014;127(01):82–6.e1
- 25 Giantonio BJ, Catalano PJ, Meropol NJ, et al; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. *J Clin Oncol* 2007;25(12):1539–1544
- 26 Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 2004;350(23):2335–2342
- 27 Van Cutsem E, Rivera F, Berry S, et al; First BEAT Investigators. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. *Ann Oncol* 2009;20(11):1842–1847
- 28 Flynn PJ, Sugrue MM, Purdie DM, et al. Serious bleeding events are uncommon in patients with metastatic colorectal cancer receiving bevacizumab as part of a first-line regimen: results from the BRiTE Observational Cohort Study. *J Clin Oncol* 2008;26(Suppl 15):4104
- 29 Griesinger F, Laskin JJ, Pavlakis N. Safety of first-line bevacizumab-based therapy with concomitant cardiovascular or anticoagulation medication in advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in MO19390 (SAiL). *J Clin Oncol* 2008;26(Suppl 15):8049
- 30 Hambleton J, Novotny WF, Hurwitz H, et al. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. *J Clin Oncol* 2004;22(Suppl 14):3528
- 31 Wardley A, Lohrisch C, Joy AA, et al. Effect of anticoagulation therapy on bleeding and thromboembolic events (TEs) in the AVADO phase III study of docetaxel (D) ± bevacizumab (BV) in inoperable locally recurrent (LR) or metastatic breast cancer (mBC). *Cancer Res* 2009;69(Suppl 2):1035
- 32 Leighl NB, Bennaoui J, Yi J, Moore N, Hambleton J, Hurwitz H. Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. *Br J Cancer* 2011;104(03):413–418
- 33 Hurwitz H, Saltz LB, Van Cutsem E, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. *J Clin Oncol* 2011;29(13):1757–1764
- 34 Abdel-Razeq H, Mansour A, Ismael Y, Abdulelah H. Inferior vena cava filters in cancer patients: to filter or not to filter. *Ther Clin Risk Manag* 2011;7:99–102
- 35 Mansour A, Ismael Y, Abdel-Razeq H. Inferior vena cava filters in patients with advanced-stage cancer. *Hematol Oncol Stem Cell Ther* 2014;7(04):136–141
- 36 Barginear MF, Gralla RJ, Bradley TP, et al. Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial. *Support Care Cancer* 2012;20(11):2865–2872
- 37 Mikhail S, Hannan L, Pishvaian MJ, Kessler C. Retrievable inferior vena cava filters in patients with cancer are safe but are they beneficial? *Med Oncol* 2015;32(06):622
- 38 Abtahian F, Hawkins BM, Ryan DP, et al. Inferior vena cava filter usage, complications, and retrieval rate in cancer patients. *Am J Med* 2014;127(11):1111–1117
- 39 Brunson A, Ho G, White R, Wun T. Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE) does not improve clinical outcomes: a population-based study. *Thromb Res* 2017;153:57–64
- 40 Coombs C, Kuk D, Devlin S, et al. Outcomes after inferior vena cava filter placement in cancer patients diagnosed with pulmonary embolism: risk for recurrent venous thromboembolism. *J Thromb Thrombolysis* 2017;44(04):489–493
- 41 Carrier M, Khorana AA, Zwicker J, Noble S, Lee AY; Subcommittee on Haemostasis and Malignancy within the SSC of the ISTH. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. *J Thromb Haemost* 2013;11(09):1760–1765
- 42 Lyman GH, Bohlke K, Khorana AA, et al; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline update 2014. *J Clin Oncol* 2015;33(06):654–656
- 43 Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease. Chest guideline and expert panel report. *Chest* 2016;149(02):315–352
- 44 Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. *Lancet Oncol* 2016;17(10):e452–e466
- 45 Duffett L, Carrier M. Inferior vena cava filters. *J Thromb Haemost* 2017;15(01):3–12
- 46 Pandhi MB, Desai KR, Ryu RK, Lewandowski RJ. The role of inferior vena cava filters in cancer patients. *Semin Intervent Radiol* 2016;33(02):71–74
- 47 American Society of Hematology. Ten things physicians and patients should question. Available at: <http://www.choosingwisely.org/wp-content/uploads/2015/02/ASH-Choosing-Wisely-List.pdf>. Accessed October 15, 2018
- 48 Lee AY, Peterson EA. Treatment of cancer-associated thrombosis. *Blood* 2013;122(14):2310–2317
- 49 Elalamy I, Mahé I, Ageno W, Meyer G. Long-term treatment of cancer-associated thrombosis: the choice of the optimal anticoagulant. *J Thromb Haemost* 2017;15(05):848–857
- 50 Francis CW, Kessler CM, Goldhaber SZ, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. *J Thromb Haemost* 2015;13(06):1028–1035
- 51 Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T, et al. Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study. *Thromb Res* 2017;157:90–96
- 52 Noble S, Sui J. The treatment of cancer associated thrombosis: does one size fit all? Who should get LMWH/warfarin/DOACs?. *Thromb Res* 2016;140(Suppl 1):S154–S159
- 53 Zwicker JI, Bauer KA. How long is long enough? Extended anticoagulation for the treatment of cancer-associated deep vein thrombosis. *J Clin Oncol* 2014;32(32):3596–3599
- 54 Raskob GE, van Es N, Verhamme P, et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. *N Engl J Med* 2018;378(07):615–624
- 55 Lee AY, Levine MN, Baker RI, et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. *N Engl J Med* 2003;349(02):146–153
- 56 Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). *J Clin Oncol* 2018;36(20):2017–2023
- 57 Streiff MB, Holmstrom B, Ashrani A, et al. Cancer-associated venous thromboembolic disease, version 1.2015. *J Natl Compr Canc Netw* 2015;13(09):1079–1095
- 58 Olmos VP, Ramos Gallo MJ, Rebollo MA, et al; Sociedad Española de Oncología Médica (SEOM); Sociedad Española de Angiología y Cirugía Vasculard (SEACV). Manejo de la enfermedad tromboembólica venosa en pacientes oncológicos: guías de práctica clínica española. Consenso SEACV-SEOM. *Med Clin (Barc)* 2015;144(Suppl 1):3–15
- 59 Debourdeau P, Farge D, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. *J Thromb Haemost* 2013;11(01):71–80



- 60 Baumann Kreuziger L, Cote L, Verhamme P, et al; RIETE Investigators. A RIETE registry analysis of recurrent thromboembolism and hemorrhage in patients with catheter-related thrombosis. *J Vasc Surg Venous Lymphat Disord* 2015;3(03):243–50.e1
- 61 Delluc A, Le Gal G, Scarvelis D, Carrier M. Outcome of central venous catheter associated upper extremity deep vein thrombosis in cancer patients. *Thromb Res* 2015;135(02):298–302
- 62 Levin JM, Schiff D, Loeffler JS, Fine HA, Black PM, Wen PY. Complications of therapy for venous thromboembolic disease in patients with brain tumors. *Neurology* 1993;43(06):1111–1114
- 63 Donato J, Campigotto F, Uhlmann EJ, et al. Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. *Blood* 2015;126(04):494–499
- 64 Chai-Adisaksopha C, Linkins LA, AlKindi SY, Cheah M, Crowther MA, Iorio A. Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours. *Thromb Haemost* 2017;117(03):589–594
- 65 Zwicker JI, Karp Leaf R, Carrier M. A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation. *J Thromb Haemost* 2016;14(09):1736–1740
- 66 Ageno W, Riva N, Schulman S, et al. Long-term clinical outcomes of splanchnic vein thrombosis. Results of an International Registry. *JAMA Intern Med* 2015;175(09):1474–1480
- 67 Riva N, Ageno W, Schulman S, et al; International Registry on Splanchnic Vein Thrombosis (IRSVT) study group. Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. *Lancet Haematol* 2016;3(06):e267–e275
- 68 Tufano A, Ageno W, Di Micco P, et al; RIETE Investigators. Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis. *Thromb Res* 2018;164:69–74
- 69 Easaw JC, Shea-Budgell MA, Wu CM, et al. Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment. *Curr Oncol* 2015;22(02):144–155
- 70 Oo TH. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH: a rebuttal. *J Thromb Haemost* 2014;12(01):115–116
- 71 Ibrahim RB, Skewes MD, Kuriakose P. “Sailing in troubled waters”: a review of the use of anticoagulation in adult cancer patients with thrombocytopenia. *Blood Coagul Fibrinolysis* 2016;27(06):615–630
- 72 Samuelson Bannow BT, Walter RB, Gernsheimer TB, Garcia DA. Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes. *J Thromb Thrombolysis* 2017;44(04):442–447
- 73 Mantha S, Miao Y, Wills J, Parameswaran R, Soff GA. Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study. *J Thromb Thrombolysis* 2017;43(04):514–518
- 74 Samuelson Bannow BT, Lee A, Khorana AA, et al. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. *J Thromb Haemost* 2018;16(06):1246–1249
- 75 Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Büller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. *J Clin Oncol* 2000;18(17):3078–3083
- 76 Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8<sup>th</sup> edition). *Chest* 2008;133(6, Suppl):141S–159S
- 77 Macle L, Cairns J, Leblanc K, et al; CCS Atrial Fibrillation Guidelines Committee. 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. *Can J Cardiol* 2016;32(10):1170–1185
- 78 You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9<sup>th</sup> ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141(2, Suppl):e531S–e575S
- 79 Rubboli A, Halperin JL, Airaksinen KE, et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. *Ann Med* 2008;40(06):428–436
- 80 Kirchhof P, Benussi S, Kotecha D, et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J* 2016;37(38):2893–2962
- 81 Martin K. Risk factors for and management of MPN-associated bleeding and thrombosis. *Curr Hematol Malig Rep* 2017;12(05):389–396
- 82 Landolfi R, Marchioli R, Kutti J, et al; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. *N Engl J Med* 2004;350(02):114–124
- 83 De Stefano V, Za T, Rossi E, et al; GIMEMA CMD-Working Party. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. *Haematologica* 2008;93(03):372–380
- 84 Lee AYY, Kamphuisen PW, Meyer G, et al; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. *JAMA* 2015;314(07):677–686
- 85 Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. *Arch Intern Med* 2002;162(15):1729–1735
- 86 Kreuziger LB, Streiff M. Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer. *Hematology (Am Soc Hematol Educ Program)* 2016;2016(01):206–207
- 87 Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9<sup>th</sup> ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141(2, Suppl):e24S–e43S
- 88 Muñoz Martín AJ, Font Puig C, Navarro Martín LM, Borrega García P, Martín Jiménez M; Spanish Society for Medical Oncology. Clinical guide SEOM on venous thromboembolism in cancer patients. *Clin Transl Oncol* 2014;16(12):1079–1090
- 89 Lim W. Using low molecular weight heparin in special patient populations. *J Thromb Thrombolysis* 2010;29(02):233–240
- 90 Connors JM. Thrombophilia testing and venous thrombosis. *N Engl J Med* 2017;377(12):1177–1187
- 91 Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9<sup>th</sup> ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2012;141(2, Suppl):e419S–e496S
- 92 Baglin T, Bauer K, Douketis J, Buller H, Srivastava A, Johnson G; SSC of the ISTH. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH. *J Thromb Haemost* 2012;10(04):698–702
- 93 Howard LS, Hughes RJ. NICE guideline: management of venous thromboembolic diseases and role of thrombophilia testing. *Thorax* 2013;68(04):391–393
- 94 Horowitz N, Brenner B. Thrombophilia and cancer. *Pathophysiol Haemost Thromb* 2008;36(3–4):131–136
- 95 Baglin T, Gray E, Greaves M, et al; British Committee for Standards in Haematology. Clinical guidelines for testing for heritable thrombophilia. *Br J Haematol* 2010;149(02):209–220
- 96 van Sluis GL, Söhne M, El Kheir DY, Tanck MW, Gerdes VE, Büller HR. Family history and inherited thrombophilia. *J Thromb Haemost* 2006;4(10):2182–2187